Protac Targeted Protein Degradation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property | Value |
|---|---|
| Category | Experimental Therapy |
| Target | Disease-causing proteins |
| Diseases | Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, ALS |
| Key Items | ARV-110, Molecular glues, AUTAC, LYTAC |
| Mechanism | Ubiquitin-proteasome system recruitment |
PROTACs (Proteolysis-Targeting Chimeras) are bifunctional molecules that harness the cell's own ubiquitin-proteasome system to selectively degrade disease-causing proteins. This represents a paradigm shift from traditional inhibition to actual elimination of target proteins. A single PROTAC molecule can degrade multiple target proteins through catalytic activity. ## Mechanism of Action
PROTACs work through a three-step process:
Binding: The PROTAC molecule binds simultaneously to:
Ubiquitination: The proximity of the target protein to the E3 ligase leads to polyubiquitination
Degradation: The tagged protein is recognized and degraded by the 26S proteasome
| Compound | Company | Target | Phase |
|---|---|---|---|
| ARV-110 | Arvinas | AR-V7 | Phase 2 |
| ARV-471 | Arvinas | ER | Phase 2 |
| DT2216 | Dialectic | MCL-1 | Phase 1 |
| B6H10 | Research | Huntingtin | Preclinical |
The study of Protac Targeted Protein Degradation Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.